ArticleCell communication and signaling : CCS2026
Resveratrol attenuates diabetic RGC degeneration through TRIM23-dependent VDAC1 ubiquitination and mitophagy.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRetinal ganglion cells (RGCs) degeneration is an early event in diabetic retinopathy (DR), tightly coupled to mitochondrial dysfunction. While the mitochondrial gatekeeper voltage-dependent anion channel 1(VDAC1) is a known mediator of apoptosis, its regulation and therapeutic targeting in diabetic RGCs remain unclear.
methodsWe examined VDAC1 expression in human donor retinas, streptozotocin-induced diabetic mice, and high glucose-treated SH-SY5Y cells. VDAC1-knockdown SH-SY5Y cells were established to explore its functional role in the context. Using virtual screening and molecular docking, we identified resveratrol (RSV) as a potential VDAC1 inhibitor, which was further validated by surface plasmon resonance binding assays and RSV-based pull-down experiments. The effects of RSV were assessed by RGCs survival, retinal electrophysiological function, and mitochondrial quality control. Tripartite motif-containing 23 (TRIM23)-VDAC1 interaction along with ubiquitination modifications were confirmed by co-immunoprecipitation. Finally, combination therapy involving RSV and adeno-associated virus serotype 2 (AAV2) carrying the γ-synuclein (SNCG) promoter mediated Trim23 overexpression was applied in both DR and acute ocular hypertension (AOH) animal models.
resultsVDAC1 was upregulated in diabetic RGCs, and its knockdown was protective. We further discovered that RSV recruits the E3 ligase TRIM23 to VDAC1, inducing a K27-linked ubiquitination switch that promotes mitophagy instead of apoptosis. We propose that RSV binding acts as an allosteric switch, reconfiguring VDAC1 to favor this protective ubiquitination pathway. Consequently, RSV restored mitochondrial health and RGCs viability. Therapeutically, enhancing this axis via RSV and RGCs-targeted Trim23 overexpression synergistically protected against RGCs loss in both DR and AOH models.
conclusionOur study unveils a pharmacologically inducible switch wherein RSV, via direct VDAC1 binding, redirects its function toward TRIM23-mediated K27-linked ubiquitination and mitophagy. The TRIM23-VDAC1 allosteric axis represents a novel therapeutic paradigm for neuroprotective intervention in DR and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.